# GV20 Oncotherapy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gv20-oncotherapy

- Industry: Healthcare Specialists
- Headquarters: Shanghai, China
- Website: www.gv20oncotherapy.com
- Latest round: Series B (Oct 14, 2021)
- Investors on record: 7

## About

Established in 2016 and based in Shanghai, China, GV20 Oncotherapy is a company that focuses on selecting effective targets cancer drugs. It also develops approached to cancer diagnosis and therapy. The company has completed 3 rounds of funding as of 2021. The company mainly involved in the field of gene editing library screening, bioinformatics and big data analysis.

The company main business is technology consulting, technology development, technology services, technology transfer in the fields of biotechnology and medical technology. The company have self developed GV20 unique platforms, GV20 genomics platform and GV20 AI (artificial intelligence) platform that provides a portfolio of immuno-oncology antibody drug solution for customers.

## Funding rounds

- Series B, Oct 14, 2021 — IDG Capital, Coatue Management, 3W Ventures, Watson Capital Advisors, Linear Capital
- Angel, Oct 2, 2018 — IDG Capital, Linear Capital, Watson Capital
- Seed, Oct 24, 2017 — IDG Capital, Linear Capital, Waston Fund

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Seed, Angel, Series B
- Linear Capital (https://capitalatlas.ai/funds/linear-capital) — Seed, Angel, Series B
- Waston Fund — Seed
- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Angel
- Coatue Management (https://capitalatlas.ai/funds/coatue-management) — Series B
- 3W Ventures (https://capitalatlas.ai/funds/3w-ventures) — Series B
- Watson Capital Advisors — Series B